Abstract：
The retinal pigmented epithelium (RPE) plays a pivotal role in retinal homeostasis. It is therefore an interesting target to fill the unmet medical need of different retinal diseases, including age-related macular degeneration and Stargardt disease. RPE replacement therapy may use different cellular sources: induced pluripotent stem cells or embryonic stem cells. Cells can be transferred as suspension on a patch with different surgical approaches. Results are promising although based on very limited samples. In this review, we summarize the current progress of RPE replacement and provide a comparative assessment of different published approaches which may become standard of care in the future.
摘要：
视网膜色素上皮（RPE）在视网膜稳态中起关键作用。因此，填补不同视网膜疾病未满足的医疗需求是一个有趣的目标，包括年龄相关性黄斑变性和Stargardt病。RPE替代疗法可以使用不同的细胞来源:诱导多能干细胞或胚胎干细胞。可以用不同的手术方法将细胞作为悬浮液转移到贴片上。尽管基于非常有限的样品,但结果是有希望的。在这次审查中,我们总结了目前RPE替代治疗的进展,并对未来可能成为标准治疗的不同已发表方法进行了比较评估.
